A cholesterol-dependent CD20 epitope detected by the FMC7 antibody

Leukemia

Volumn 17, Issue 7, 2003, Pages 1384-1389

  Polyak, M J ^a   Ayer, L M ^a   Szczepek, A J ^b   Deans, J P ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

Author keywords

CD20; Cholesterol; Epitope; FMC7

Indexed keywords

CD20 ANTIGEN; CD23 ANTIGEN; CD5 ANTIGEN; CELL SURFACE MARKER; CHOLESTEROL; DETERGENT; EPITOPE; MONOCLONAL ANTIBODY;

ANTIGEN BINDING; ANTIGEN EXPRESSION; ARTICLE; B CELL LEUKEMIA; B CELL LYMPHOMA; B LYMPHOCYTE; BIOLOGICAL MONITORING; CANCER CLASSIFICATION; CANCER THERAPY; CELL LINE; CELL LINEAGE; CELL MEMBRANE; CONFORMATION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; GENE EXPRESSION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LEUKEMIA; LYMPHOMA; PRIORITY JOURNAL; REGULATORY MECHANISM; SOLUBILITY; TEMPERATURE DEPENDENCE;

EID: 0038442252     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402978     Document Type: Article

References (42)

1. Matutes E, Owusu-Ankomah K, Morilla R, Garcia Marco J, Houlihan A, Que TH et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 1994; 8: 1640-1645.
2. DiGiuseppe JA, Borowitz MJ. Clinical utility of flow cytometry in the chronic lymphoid leukemias. Semin Oncol 1998; 25: 6-10.
3. D'Arena G, Musto P, Cascavilla N, Dell'Olio M, Di Renzo N, Carotenuto M. Quantitative flow cytometry for the differential diagnosis of leukemic B-cell chronic lymphoproliferative disorders. Am J Hematol 2000; 64: 275-281.
4. Garcia DP, Rooney MT, Ahmad E, Davis BH. Diagnostic usefulness of CD23 and FMC-7 antigen expression patterns in B-cell lymphoma classification. Am J Clin Pathol 2001; 115: 258-265.
5. Serke S, Schwaner I, Yordanova M, Szczepek A, Huhn D. Monoclonal antibody FMC7 detects a conformational epitope on the CD20 molecule: evidence from phenotyping after rituxan therapy and transfectant cell analyses. Cytometry 2001; 46: 98-104.
6. Rosenthal P, Rimm IJ, Umiel T, Griffin JD, Osathanondh R, Schlossman SF et al. Ontogeny of human hematopoietic cells: analysis utilizing monoclonal antibodies. J Immunol 1983; 131: 232-237.
7. Brooks DA, Beckman IG, Bradley J, McNamara PJ, Thomas ME, Zola H. Human lymphocyte markers defined by antibodies derived from somatic cell hybrids. IV. A monoclonal antibody reacting specifically with a subpopulation of human B lymphocytes. J Immunol 1981; 126: 1373-1377.
8. Zola H, McNamara PJ, Moore HA, Smart IJ, Brooks DA, Beckman IG et al. Maturation of human B lymphocytes-studies with a panel of monoclonal antibodies against membrane antigens. Clin Exp Immunol 1983; 52: 655-664.
9. Bloem AC, Chand MA, Dollekamp I, Rijkers GT. Functional properties of human B-cell subpopulations defined by monoclonal antibodies HB4 and FMC7. J Immunol 1988; 140: 768-773.
10. Rijkers GT, Dollekamp I, Zegers BJ. Evidence that FMC7 is a human B-cell differentiation antigen. Immunol Lett 1990; 24: 261-264.
11. Hubl W, Iturraspe J, Braylan RC. FMC7 antigen expression on normal and malignant B-cells can be predicted by expression of CD20. Cytometry 1998; 34: 71-74.
12. Zola H, Neoh SH, Potter A, Melo JV, De Oliveria MS, Catovsky D. Markers of differentiated B-cell leukaemia: CD22 antibodies and FMC7 react with different molecules. Dis Markers 1987; 5: 227-235.
13. Catovsky D, Cherchi M, Brookss D, Bradely J, Zola H. Hetero-geneity of B-cell leukemias demonstrated by the monoclonal antibody FMC7. Blood 1981; 58: 406-408.
14. Huh YO, Pugh WC, Kantarjian HM, Stass SA, Cork A, Trujillo JM et al. Detection of subgroups of chronic B-cell leukemias by FMC7 monoclonal antibody. Am J Clin Pathol 1994; 101: 283-289.
15. Scott CS, Limbert HJ, MacKarill ID, Roberts BE. Membrane phenotypic studies in B-cell lymphoproliferative disorders. J Clin Pathol 1985; 38: 995-1001.
16. Almasri NM, Duque RE, Iturraspe J, Everett E, Braylan RC. Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia. Am J Hematol 1992; 40: 259-263.
17. D'Hautcourt JL, Isaac J. Mean fluorescence intensity of dual stained cells. Cytometry 1999; 38: 44-46.
18. Ahmad E, Garcia D, Davis BH. Clinical utility of CD23 and FMC7 antigen coexistent expression in B-cell lymphoproliferative disorder subclassification. Cytometry 2002; 50: 1-7.
19. Deans JP, Kalt L, Ledbetter JA, Schieven GL, Bolen JB, Johnson P. Association of 75/80-kDa phosphoproteins and the tyrosine kinases Lyn, Fyn, and Lck with the B-cell molecule CD20. Evidence against involvement of the cytoplasmic regions of CD20. J Biol Chem 1995; 270: 22632-22638.
20. Polyak MJ, Deans JP. Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure. Blood 2002; 99: 3256-3262.
21. Karasuyama H, Kudo A, Melchers F. The proteins encoded by the VpreB and lambda 5 pre- B-cell -specific genes can associate with each other and with mu heavy chain. J Exp Med 1990; 172: 969-972.
22. Deans JP, Robbins SM, Polyak MJ, Savage JA. Rapid redistribution of CD20 to a low density detergent-insoluble membrane compartment. J Biol Chem 1998; 273: 344-348.
23. Inbar M. Fluidity of membrane lipids: a single cell analysis of mouse normal lymphocytes and malignant lymphoma cells. FEBS Lett 1976; 67: 180-185.
24. Ohtani Y, Irie T, Uekama K, Fukunaga K, Pitha J. Differential effects of alpha-, beta- and gamma-cyclodextrins on human erythrocytes. Eur J Biochem 1989; 186: 17-22.
25. Yancey PG, Rodrigueza WV, Kilsdonk EP, Stoudt GW, Johnson WJ, Phillips MC et al. Cellular cholesterol efflux mediated by cyclodextrins. Demonstration of kinetic pools and mechanism of efflux. J Biol Chem 1996; 271: 16026-16034.
26. Simons K, Ikonen E. Functional rafts in cell membranes. Nature 1997; 387: 569-572.
27. Brown DA, London E. Structure and function of sphingolipid- and cholesterol-rich membrane rafts. J Biol Chem 2000; 275: 17221-17224.
28. Gimpl G, Burger K, Politowska E, Ciarkowski J, Fahrenholz F. Oxytocin receptors and cholesterol: interaction and regulation. Exp Physiol 2000; 85: 41S-49S.
29. Jones OT, McNamee MG. Annular and nonannular binding sites for cholesterol associated with the nicotinic acetylcholine receptor. Biochemistry 1988; 27: 2364-2374.
30. Klein U, Gimpl G, Fahrenholz F. Alteration of the myometrial plasma membrane cholesterol content with beta-cyclodextrin modulates the binding affinity of the oxytocin receptor. Biochemistry 1995; 34: 13784-13793.
31. Fahrenholz F, Klein U, Gimpl G. Conversion of the myometrial oxytocin receptor from low to high affinity state by cholesterol. Adv Exp Med Biol 1995; 395: 311-319.
32. Narayanaswami V, McNamee MG. Protein-lipid interactions and Torpedo californica nicotinic acetylcholine receptor function. 2. Membrane fluidity and ligand-mediated alteration in the accessibility of gamma subunit cysteine residues to cholesterol. Biochemistry 1993; 32: 12420-12427.
33. 2+ conductance found constitutively in B lymphocytes. J Cell Biol 1993; 121: 1121-1132.
34. Kanzaki M, Shibata H, Mogami H, Kojima I. Expression of calcium-permeable cation channel CD20 accelerates progression through the G1 phase in Balb/c 3T3 cells. J Biol Chem 1995; 270: 13099-13104.
35. Deans JP, Kalt L, Ledbetter JA, Schieven GL, Bolen JB, Johnson P. Association of 75/80-kDa phosphoproteins and the tyrosine kinases Lyn, Fyn, and Lck with the B-cell molecule CD20. Evidence against involvement of the cytoplasmic regions of CD20. J Biol Chem 1995; 270: 22632-22638.
36. Popoff IJ, Savage JA, Blake J, Johnson P, Deans JP. The association between CD20 and Src-family tyrosine kinases requires an additional factor. Mol Immunol 1998; 35: 207-214.
37. Deans JP, Li H, Polyak MJ. CD20-mediated apoptosis: signalling through lipid rafts. Immunology 2002; 107: 176-182.
38. Hofmeister JK, Cooney D, Coggeshall KM. Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis. Blood Cells Mol Dis 2000; 26: 133-143.
39. Shan D, Ledbetter JA, Press OW. Signaling events involved in anti-CD20-induced apoptosis of malignant human B-cells. Cancer Immunol Immunother 2000; 48: 673-683.
40. Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol 2002; 29: 2-9.
41. Cragg MS, Morgan SM, Chan HT, Morgan BP, Filatov AV, Johnson PW et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 2003; 101: 1045-1052.
42. Sherbet GV. Membrane fluidity and cancer metastasis. Exp Cell Biol 1989; 57: 198-205.